Pancreas

A patient with newly diagnosed gallstone pancreatitis and chronic kidney disease sits at the center of a strategy the field itself changed recently — the debate isn't whether to give fluids, but how a trial that stopped early for harm actually applies to a kidney with less room to give.

A guideline recommends against pancreatic enzymes for pain specifically — not for exocrine insufficiency, where they remain standard. The question here is whether one patient's own imaging is reason enough to try them anyway.

Six years of progressive, calcific chronic pancreatitis have left one patient's pain objectively worse on imaging and on his own report — the disagreement is how far a non-cancer diagnosis should still be allowed to climb the same ladder built for cancer pain.

Two real randomized trials of the same antioxidant combination for chronic pancreatitis pain reached opposite conclusions — one patient's own lab work is the closest thing the team has to deciding which trial's population she actually belongs to.

A patient whose enteric-coated enzymes have already fixed his malabsorption still has real pain — the question is whether the coating that makes the drug work for one problem is exactly what keeps it from working on the other.

Two clean steroid responses, two relapses once the taper finished — the question is whether a third round of the therapy that has already stopped holding is still the right first move.

Type 1 and Type 2 autoimmune pancreatitis are both steroid-responsive by definition — the pivot here isn't which one, it's how differently that shared label plays out once organ involvement, relapse risk, and a patient's own other diagnoses enter the picture.

A large, still-expanding area of pancreatic necrosis tempts the team toward starting antibiotics before any sign of infection — against a guideline built on trial evidence that found exactly that instinct doesn't help.

A patient stacking three independent risk factors for post-ERCP pancreatitis turns a routine prophylaxis choice into a real question about whether one well-studied measure is enough, or whether her risk profile calls for the combination.

A technically difficult cannulation raises the temptation to add every plausible layer of prophylaxis available — the question is whether octreotide's mechanism is enough reason to add it when its own trial record hasn't consistently backed it up.

A patient's ileus makes feeding her gut look like the harder, less reliable option — the trial evidence behind enteral nutrition argues that's exactly the situation it was built to answer.

A low fecal elastase four weeks after a severe pancreatitis episode could mean lasting exocrine damage — or a gland still mid-recovery. The question is whether treating now forecloses finding out which.

A triglyceride level high enough to cause pancreatitis on its own forces a choice between two clearance strategies with almost no head-to-head trial evidence deciding between them — only what the patient's own trajectory is doing right now.

A patient's new diabetes diagnosis looks, on paper, like it could start on an oral agent — until his damaged alpha cells, not just his beta cells, become the reason that choice carries more risk than it would in ordinary Type 2 disease.

An asymptomatic but steadily growing pseudocyst puts a genuinely lower-risk medical option against a proceduralist's read that waiting only makes the eventual drainage harder.

A groove mass that looks inflammatory on every clinical clue available still can't be told apart from cancer without tissue — the disagreement is whether a medical trial is a reasonable first step, or a reasonable delay of the one test that would actually settle it.

The one drug that has kept her Crohn's disease genuinely controlled is also the one that just put her in the hospital with acute pancreatitis — the question is whether one episode closes the door on it for good.

Large trials say the class isn't linked to pancreatitis at the population level — one patient's own clean, temporally plausible episode is asking whether that population answer is actually the question she needs answered.

A modest trial benefit for a procedure that slows opioid escalation rather than replacing it forces a real question about how much invasive intervention is worth pursuing for pain that conservative titration is, for now, still managing.

A CFTR modulator that was never prescribed for her digestion has changed how she digests anyway — the question is whether her own improved symptoms are reliable enough evidence to actually lower a dose she's carried since infancy. ---